Dexamethasone augmentation in treatment-resistant depression
Dexamethasone augmentation in treatment-resistant depression
复制标题
DOI：
10.1111/j.1600-0447.1997.tb00374.x
复制
发表时间：
1997-01-01
影响因子：
6.7
通讯作者：
Berti, C
中科院分区：
文献类型：
--
作者：
Dinan, TG;Lavelle, E;Berti, C
共招募了10名符合《精神疾病诊断与统计手册》第三版修订本（DSM - III - R）中重度抑郁症标准的患者参与研究，这些患者在接受舍曲林或氟西汀为期6周的治疗后均未见效。每位受试者都进行了基线血清皮质醇测量以及汉密尔顿抑郁量表（HAMD）评分。所有患者在继续抗抑郁治疗的同时，开始服用地塞米松（每日3毫克），持续4天。在第5天和第21天再次进行汉密尔顿量表评分。6名患者有显著改善，2名患者有轻微反应。良好的临床反应与较高的基线皮质醇水平相关。
A total of 10 patients who fulfilled DSM-III-R criteria for major depression were recruited to the study, each of whom had failed to respond to a 6-week course of treatment with either sertraline or fluoxetine. Each subject had baseline serum cortisol measurements together with a Hamilton depression (HAMD) score. All patients were started on dexamethasone (3 mg daily) for 4 days, while remaining on their antidepressant treatment. Further Hamilton ratings were made on days 5 and 21. Six patients showed a significant improvement, whilst two showed a minimal response. A good clinical response was associated with a high baseline cortisol level.